BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

838 related articles for article (PubMed ID: 18097455)

  • 21. [Croatian guideliness for prevention of chemotherapy induced nausea and vomiting].
    Tomek R; Vrdoljak E; Vrbanec D; Nemet D; Matković V; Plestina S; Gugić D; Dintinjana RD; Bolanca A; Samarzija M; Petković M
    Lijec Vjesn; 2009; 131(3-4):49-53. PubMed ID: 19514248
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of chemotherapy-related nausea and vomiting using a serotonin antagonist.
    Egan AP; Taggart JR; Bender CM
    Oncol Nurs Forum; 1992 Jun; 19(5):791-5. PubMed ID: 1535124
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Chemotherapy induced-vomiting--a practical guide for prevention and therapy].
    Jordan K; Voigt W; Schmoll HJ
    Dtsch Med Wochenschr; 2006 Aug; 131(34-35):1869-72. PubMed ID: 16915549
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Best practice management of CINV in oncology patients: II. Antiemetic guidelines and rationale for use.
    Wickham R
    J Support Oncol; 2010; 8(2 Suppl 1):10-5. PubMed ID: 20629453
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis.
    Slatkin NE
    J Support Oncol; 2007 May; 5(5 Suppl 3):1-9. PubMed ID: 17566383
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [An assessment tool for chemotherapy-induced nausea and vomiting and intervention outcomes].
    Aimono Y; Suzuki S; Nemoto M; Saito Y; Aoyama Y; Joko F; Maruyama T; Kamoshida T
    Gan To Kagaku Ryoho; 2013 Dec; 40(13):2551-4. PubMed ID: 24335368
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of nausea and vomiting caused by anticancer drugs: state of the art.
    Pisters KM; Kris MG
    Oncology (Williston Park); 1992 Feb; 6(2 Suppl):99-104. PubMed ID: 1532744
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multinational Association of Supportive Cancer Care (MASCC).
    Roila F;
    Support Care Cancer; 2003 Apr; 11(4):260-1. PubMed ID: 12749339
    [No Abstract]   [Full Text] [Related]  

  • 29. [Drug treatment of nausea and vomiting caused by cancer chemotherapy].
    Havsteen H; Kjaer M
    Ugeskr Laeger; 1989 Feb; 151(7):430-4. PubMed ID: 2645736
    [TBL] [Abstract][Full Text] [Related]  

  • 30. International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice.
    Jordan K; Gralla R; Jahn F; Molassiotis A
    Eur J Pharmacol; 2014 Jan; 722():197-202. PubMed ID: 24157984
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The use of antiemetics in cancer chemotherapy].
    Ghosn M; Droz JP
    J Med Liban; 1992; 40(2):106-7. PubMed ID: 1339878
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 2016 Updated MASCC/ESMO Consensus Recommendations: Controlling nausea and vomiting with chemotherapy of low or minimal emetic potential.
    Olver I; Ruhlmann CH; Jahn F; Schwartzberg L; Rapoport B; Rittenberg CN; Clark-Snow R
    Support Care Cancer; 2017 Jan; 25(1):297-301. PubMed ID: 27572335
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Guidelines for the control of nausea and vomiting with chemotherapy of low or minimal emetic potential.
    Olver I; Clark-Snow RA; Ballatori E; Espersen BT; Bria E; Jordan K
    Support Care Cancer; 2011 Mar; 19 Suppl 1():S33-6. PubMed ID: 20803222
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide.
    Shih V; Wan HS; Chan A
    Ann Pharmacother; 2009 Mar; 43(3):444-52. PubMed ID: 19193584
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical practice guidelines on antiemetics in oncology.
    Aranda Aguilar E; Constenla Figueiras M; Cortes-Funes H; Diaz-Rubio García E; Gascon Vilaplana P; Guillém V; Martin-Algarra S
    Expert Rev Anticancer Ther; 2005 Dec; 5(6):963-72. PubMed ID: 16336087
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NCCN antiemesis guidelines emphasize 'delayed' emesis, new 5-HT3 inhibitors, and NK-1 blockers.
    National Comprehensive Cancer Network (NCCN)
    J Support Oncol; 2004; 2(4):366. PubMed ID: 15357520
    [No Abstract]   [Full Text] [Related]  

  • 37. Putting evidence into practice: evidence-based interventions to prevent, manage, and treat chemotherapy-induced nausea and vomiting.
    Tipton JM; McDaniel RW; Barbour L; Johnston MP; Kayne M; LeRoy P; Ripple ML
    Clin J Oncol Nurs; 2007 Feb; 11(1):69-78. PubMed ID: 17441398
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nausea and vomiting with high-dose chemotherapy and stem cell rescue therapy: a review of antiemetic regimens.
    Trigg ME; Inverso DM
    Bone Marrow Transplant; 2008 Oct; 42(8):501-6. PubMed ID: 18724391
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent advances and updated guidelines in the management of chemotherapy-induced nausea and vomiting.
    Schwartzberg LS; Grunberg SM; Kris MG
    Clin Adv Hematol Oncol; 2011 Nov; 9(11 Suppl 27):1-14; quiz 15-6. PubMed ID: 22362372
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
    Hamadani M; Chaudhary L; Awan FT; Khan JK; Kojouri K; Ozer H; Tfayli A
    J Oncol Pharm Pract; 2007 Jun; 13(2):69-75. PubMed ID: 17873106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.